These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4441828)

  • 21. Propranolol and depression: a reevaluation based on a pilot clinical trial.
    Stoudemire A; Brown JT; Harris RT; Blessing-Feussner C; Roberts JH; Nichols JC; Houpt JL
    Psychiatr Med; 1984 Jun; 2(2):211-8. PubMed ID: 6400597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia.
    Wilson JD; King DJ; Sheridan B
    Br J Clin Pharmacol; 1979 Mar; 7(3):313-4. PubMed ID: 427008
    [No Abstract]   [Full Text] [Related]  

  • 24. Propranolol-associated confused states during alcohol withdrawal.
    Jacob MS; Zilm DH; MacLeod SM; Sellers EM
    J Clin Psychopharmacol; 1983 Jun; 3(3):185-7. PubMed ID: 6875027
    [No Abstract]   [Full Text] [Related]  

  • 25. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
    Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
    Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is propranolol effective in primary polydipsia?
    Kishi Y; Kurosawa H; Endo S
    Int J Psychiatry Med; 1998; 28(3):315-25. PubMed ID: 9844835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed-Onset Hypnopompic Visual Hallucinations 20 Years After Initiation of Propranolol Therapy for Systemic Hypertension: A Case Report.
    Au Eong DTM; Chiew RLJ; Au Eong KG
    Am J Case Rep; 2024 Jul; 25():e944342. PubMed ID: 39052542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-adrenergic blocking drugs in psychiatry: present status, future approaches and research.
    Atsmon A; Blum I
    Encephale; 1978; 4(2):173-86. PubMed ID: 28941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hallucinations and propranolol.
    Hinshelwood RD
    Br Med J; 1969 May; 2(5654):445. PubMed ID: 5781495
    [No Abstract]   [Full Text] [Related]  

  • 30. [Resistant schizophrenia: what chemotherapy?].
    Vanelle JM
    Ann Med Psychol (Paris); 1993 Apr; 151(4):346-51. PubMed ID: 7904434
    [No Abstract]   [Full Text] [Related]  

  • 31. Propranolol-induced hallucinosis.
    Horn JR; Rylander ML; Hicks HM
    Clin Pharm; 1982; 1(5):464-8. PubMed ID: 7184681
    [No Abstract]   [Full Text] [Related]  

  • 32. Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients.
    Ramsay RA; Ban TA; Lehmann HE; Saxena BM; Bennett J
    Can Med Assoc J; 1970 May; 102(9):939-42. PubMed ID: 4157149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxprenolol and propranolol in anxiety states. A double-blind comparative study.
    Becker AL
    S Afr Med J; 1976 Apr; 50(16):627-9. PubMed ID: 772831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease.
    Codaccioni JL; Orgiazzi J; Blanc P; Pugeat M; Roulier R; Carayon P
    J Clin Endocrinol Metab; 1988 Oct; 67(4):656-62. PubMed ID: 3417846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
    Elizur A; Segal S; Yeret A; Ben-David M
    Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of propranolol in infantile haemangioma among Chinese children.
    Chik KK; Luk CK; Chan HB; Tan HY
    Hong Kong Med J; 2010 Oct; 16(5):341-6. PubMed ID: 20889997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia.
    Hayes PE; Schulz SC
    Pharmacotherapy; 1983; 3(2 Pt 1):101-17. PubMed ID: 6134273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Propranolol-Polfa in the treatment of schizophrenic psychoses].
    Sobkowiak J; Rymaszewski Z; Młyński J; Sznajderman M
    Psychiatr Pol; 1982; 16(1-2):59-65. PubMed ID: 7146208
    [No Abstract]   [Full Text] [Related]  

  • 40. A versatile new sustained-action neuroleptic: pipotiazine palmitate in psychiatric practice.
    Johnston RE; Niesink F
    J Int Med Res; 1979; 7(3):187-93. PubMed ID: 37133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.